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Summary Recent studies suggest that aberrations of c-erbB-2 may be involved in astrocytic brain tumours.
We screened immunohistochemically c-erbB-2 protein (p185) expression in 94 astrocytic grade 1-4 neoplasms
of the brain. The amplification of the c-erbB-2 oncogene was investigated in protein overexpression cases by
dual colour fluorescence in situ hybridisation (FISH). p185 overexpression was correlated with p53 and
epidermal growth factor receptor (EGFR) expression, as well as with clinicopathological features. Only two
anaplastic (grade 3) astrocytomas and one gliobastoma (grade 4) showed overexpression of p185 protein by
immunohistochemistry (monoclonal MAb antibody TA250), whereas none of the grade 1-2 astrocytomas
was positive. Interestingly, the expression of p185 was confined solely to the cytoplasm of neoplastic astrocytic
cells and not to the cell membranes as found in malignancies with amplification of the c-erbB-2 oncogene. Two
of the three overexpression cases were also positive by EGFR. No amplification of the c-erbB-2 gene was
observed by FISH in the three tumours with immunohistochemical p185 overexpression or seven weakly
positive/negative tumours. In conclusion, our results suggest that p185 overexpression is infrequent in
astrocytomas, that it is of no important diagnostic or prognostic value and that c-erbB-2 oncogene
amplification is not seen in the few cases in which there is overexpression.
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Increased expression of c-erbB-2 protein (pl85) is associated
with malignant cell transformation and poor prognosis in
several tumours (Slamon et al., 1987, 1989; Yokota et al.,
1988). p185 is a transmembrane glycoprotein of 185 kDa
with tyrosine kinase activity that shares homology with the
epidermal growth factor receptor (EGFR) (Schechter et al.,
1985; Akiyama et al., 1986) and is assumed to be involved in
the regulation of cell growth and differentiation. p185 is a
receptor for a still poorly characterised growth factor ligand
(Lupu et al., 1992). The c-erbB-2 gene is located on
chromosome 17q21 and it is often amplified in human
breast, ovarian and gastric cancer (Slamon et al., 1987, 1989;
Yokota et al., 1988). The degree of amplification is related to
p185 protein expression, high cell proliferation rate and poor
prognosis (Slamon et al., 1987, 1989).
Although amplification of the EGFR gene has been found
in astrocytic neoplasms, particularly in glioblastomas (von
Deimling et al., 1992), the role of amplification of the c-erbB-
2 gene has not been established in astrocytomas. A few
studies using cell lines or a small number of tumours have
not found abnormalities in c-erbB-2 oncogene or in its
transcription (Saxena et al., 1992; Burgart et al., 1991; Natali
et al., 1990), but two recent papers report common p185
overexpression in archival astrocytoma material (Bernstein et
al., 1993; Schwechheimer et al., 1994). The latter two studies
suggested that p185 expression could be associated with
tumorigenesis in astrocytomas, but the evaluation of the
clinical value of p185 expression was based on a very limited
subset of cases (Schwechheimer et al., 1994).
In this study p185 protein expression was evaluated
immunohistochemically in 94 archival paraffin-embedded
astrocytomas using a monoclonal antibody specific to the
external domain of the c-erbB-2 protein. The amplification of
the c-erbB-2 oncogene was investigated by the dual colour
fluorescence in situ hybridisation (FISH) method, a very
recent introduction that is applicable to archival tumour
tissues (Hyytinen et al., 1994). The association of c-erbB-2
expression with p53 and EGFR expression as well as with
clinicopathological features, was also studied.
Materials and methods
The astrocytoma material was collected at Tampere
University Hospital, Tampere, Finland between February
1988 and February 1992. Virtually all astrocytic neoplasms
from that period were sampled to our studies (Haapasalo et
al., 1993a, b). In this study tumours of 94 patients (36 women
and 58 men; median age 47 years, mean +s.d. 45+ 18, range
3-77 years) were evaluated.
The tumours were classified and graded by two
neuropathologists according to the WHO nomenclature
(Ziilch, 1979; Burger et al. 1991). Furthermore, we followed
the principle adopted in the new WHO classification
(Kleihues et al., 1993) that the lowest grade of diffuse
astrocytomas is grade 2 and pilocytic astrocytomas are of
grade 1. There were 11 grade 1 tumours (pilocytic
astrocytomas), 19 grade 2 tumours, 22 anaplastic astro-
cytomas (grade 3) and 42 glioblastomas (grade 4) in the
material. The clinical follow-up period for the survivors was
at least 24 months (follow-up time for survivors: mean+s.d.
33 + 11 months).
Immunohistochemistry
Representative sections from routinely formalin-fixed paraf-
fin-embedded blocks were cut on Vectabond-treated slides
(Vector Laboratories, Burlingame, CA, USA) and dried over-
night at room temperature. The slides were dewaxed and
rehydrated. Before c-erbB-2 staining (Kallioniemi et al.,
1991), immunoreactivity was enhanced by treatment with
0.1% protease (Nagarse, Sigma, St Louis, MO, USA) for
20 min at room temperature. The sections were stained using
the immunoperoxidase technique (Vectastain Elite; Vector)
with a mouse monoclonal MAbI antibody (4 ,ug ml-'; clone
TA250, Triton Biosciences, Alameda, CA, USA) which is
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specific to the external domain of c-erbB-2 protein and has
no cross-reactivity with EGFR. The sections were counter-
stained with haematoxylin. Paraffin-embedded breast tumour
samples with amplification of the c-erbB-2 gene according to
a Southern analysis were used as positive controls in
immunostainings. Only strong diffuse immunostaining of
the cell membrane or cytoplasm was scored as positive.
Tumours with widespread, clear staining of neoplastic cells
were considered positive, showing increased expression of
p185. In addition to the totally p185-negative tumours, the
three tumours in which only occasional cells (<1/10 high
power fields) exhibited weak positive staining were considered
negative.
Additional sections were stained either with a MAb 31G7
monoclonal antibody to human EGER (0.5 pig ml-', Triton
Diagnostics) or with a monoclonal antibody DO-7 to p513
(dilution 1: 300, Novocastra Laboratories, Newcastle, UK) as
described previously (Visakorpi et at., 1992; Haapasalo et at.,
1993a). All the evaluations were made by two observers
(p185; HHa and HHe; p53; HHa and HHe; EGFR; HHa and
PS).
-FIS_H
Sample preparation and FISH analysis were carried out
according to Hyytinen et at. (1994). The nuclei for FISH
analysis were obtained by enzymatic disaggregation of 50
micron sections of paraffin-embedded blocks (Heiden et at.,
1991). Nuclear suspension was filtered and pipetted on
Vectabond-treated slides and airdried. The slides were
incubated in 50% glycerol/0. 1 x SSC (pH 7.5) at 90'C for
3 min. They were then denatured for 5 min at 740C in a 70%
formamide/2 x SSC solution (pH 7.0), followed by dehydra-
tion in an ethanol series and incubation in proteinase K
solution (8 Mig ml-1; Sigma) in 20 mm Tris/2 mm calcium
chloride (pH 7.5) buffer for 7.5 min at 370C. Fresh tissue
samples from the BT 474 breast cancer cell line and formalin-
fixed, paraffin-embedded breast tumour tissue were used as
positive and lymphocyte samples as negative controls.
A hybridisation mixture consisting of 2.5 ng of digox-
igenin-labelled chromosome 17 centomeric probe (p17H8),
20 ng c-erbB-2 probe (cRC Neul, cRC Neu4), S pig human
placental DNA (Sigma), 50% formamide, 10% dextran
sulphate and 2 x SSC (pH 7) was denatured for 5 min at
70'C and cooled. The mixture was applied on denatured
nuclei on slides and allowed to hybridise for 2 days. The
slides were washed and stained with 5 Mg ml-' avidin-FITC
(Vector) and 1 itg ml -1anti-digoxigenin -rhodamine (Boeh-
ringer Mannheim). The FITC signal was amplified using a
biotinylated anti-avidin antibody (5 4ug ml-'; Vector) in
PNM, followed by another layer of avidin- FITC
(5 Mg ml-1 in PNM). The slides were counterstained with
1 ImM 4,6-diamidino-2-phenylindole (DAPI) in an antifade
solution.
A Nikon SA epifluorescence microscope equipped with a
63 x Plan-Apochromatic objective was used for scoring FITC
and rhodamine signals. The microscope was equipped withi a
P1 multiband pass filter system (Chroma Technology,
Brattleboro, VT, USA), which consists of a triple bandpass
beam splitter and emission filter setup and separate excitation
filters for the different fiuorochromes and fluorochrome
combinations. Hybridisation signals were scored as described
previously (Kallioniemi et~at., 1992). The hybridisation
efficiency (defined as the percentage of disomic signals in a
diploid cell) for normal lymph node cells was 75%. At least
50 cells were scored for each sample.
Results
p185-protein overexpression
Only two anaplastic (grade 3) astrocytomas and one
glioblastoma (grade 4) of the 94 grade 1-4 astrocytic
tumours studied were clearly positive for p185 protein by
immunohistochemistry. None of the pilocytic (grade 1)
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Figure 1 Immunohistochemical staining of c-erbB-2 protein
(TA250) in formalin-fixed paraffin-embedded tissues. Normal
brain tissue is negative, showing only nuclear counterstaining
with haematoxylin (a). The positivity in the anaplastic astro-
cytoma (grade 3) is diffuse and fairly intense in cytoplasm,
whereas cell membranes and nuclei are negative (b). Strong
membranous immunostaining is observed in the breast cancer
sample with demonstrated c-erbB-2 gene amplification (c) (x 400).
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Figure 2 FISH of an astrocytoma sample that showed c-erbB-2
protein overexpression immunohistochemically. Chromosome 17
centromeres are shown in red (rhodamine labelling) and
individual c-erbB-2 gene copies in green (fluorescein labelling).
Nuclei were counterstained with DAPI (blue). There is an equal
number of c-erbB-2 spots and chromosome 17 spots and therefore
there is no evidence of c-erbB-2 gene amplification.
astrocytomas or grade 2 astrocytomas expressed p185. The
positivity in the three positive tumours was diffuse and fairly
intense in cytoplasm, whereas the cell membranes and nuclei
were negative (Figure lb). By contrast, strong membranous
immunostaining was observed in the breast cancer samples
with demonstrated c-erbB-2 gene amplification (Figure lc).
Normal brain tissue and reactive astrocytes were always
p185-negative (Figure la). Of the three positive tumours, one
showed a low level of p53-positivity. EGFR was positive in
two of the three p185-positive tumours. None of the three
patients with tumours expressing p185 was alive after 14
months of follow-up, but their prognosis did not differ from
the other high-grade tumours.
c-erbB-2 amplification by FISH
All three p185-positive tumours, as well as the three tumours
in which only occasional cells (< 1/10 HPF) exhibited weak
positive staining (considered p185-negative in this study),
were analysed by FISH. In addition, four totally p185-
negative astrocytomas and one cerebral arteriovenous
malformation were included in the analysis as controls.
None of these showed c-erbB-2 gene amplification by FISH
(i.e. more than two times c-erbB-2 spots relative to
chromosome 17 spots) (Figure 2).
Discussion
It has been reported earlier that c-erbB-2 (pl85) over-
expression is associated with poor survival in several
malignancies, e.g. in breast, ovarian and gastric cancer
(Slamon et al., 1987, 1989; Yokota et al., 1988). In breast
carcinoma the c-erbB-2 gene has been found to be amplified in
up to 30% of the tumours, and there is evidence that this
amplification correlates with p185 protein expression (Clark et
al., 1991). However, a recent report on ovarian cancer suggests
that c-erbB-2 amplification is infrequent and that elevated
levels of p185 protein are not related to the amplification of
the gene or increase in mRNA (Morali et al., 1993). The
findings indicated that p185-positivity localised in cell
membrane was associated with c-erbB-2 amplification,
whereas positivity confined to the cytoplasm was not.
As far as astrocytic tumours are concerned, the evidence
from the few studies that exist on the c-erbB-2 gene and p185
protein expression is controversial. Studies using glioma cell
lines or a small number of tumours have not found
abnormalities in the c-erbB-2 oncogene or in its transcription
(Saxena et al., 1992; Burgart et al., 1991; Natali et al., 1990).
Recently, however, one study (Bernstein et al., 1993) reported
p185 immunopositivity in all grades among 24 paraffin-
embedded astrocytomas. The same source also found a
significant difference in the numbers of p185-positive cells
(human specific anti-pl85cneu, mouse monoclonal Ab3 and/or
rabbit polyclonal c-erbB-2) in high-grade vs low-grade
astrocytomas. The same trend was noticed in a large series
of fixed brain tumours (Schwechheimer et al., 1994), in which
most (82/122) astrocytic neoplasms were immunopositive by
monoclonal antibody 3B5 against p185, whereas only 40 were
negative or weakly positive. In these two studies granular
p185 immunoreaction was seen both in association with cell
membrane and in the cytoplasm.
In contrast to the findings of the latter two studies we
observed that p185 expression (monoclonal antibody TA250
specific to the external domain of c-erbB-2 protein) is
infrequent in paraffin-embedded astrocytic neoplasms and is
confined to the cytoplasm. Only three of the 64 high-grade
tumours were p185-positive, while none of the 30 low-grade
(grade 1 -2) astrocytomas showed expression. The most
probable explanation for the variation in p185 expression
lies in the efficiency of different antibodies to detect p185
amplification/overexpression: a series of different p185
antibodies were tested in paraffin-embedded breast cancer
material, previously characterised for c-erbB-2 amplification
and overexpression in frozen specimens (Press et al., 1994).
The antibody used in the present study (TA250) was shown
to have better sensitivity and specificity in the detection of
amplification and overexpression than the antibody 3B5 - an
observation that we also share (data not shown).
In line with the recent observations in ovarian and breast
cancer (Morali et al., 1993; Press et al., 1994), the p185
overexpression confined to cytoplasm of all three of our
positive cases was not associated with c-erbB-2 amplification.
The c-erbB-2 gene was not amplified in any of the ten (three
immunopositive and seven indefinitely positive/negative)
astrocytic tumours studied by dual colour FISH. The FISH
technique used in the present study was recently introduced
to improve the analysis of interphase nuclei of tumours that
have been extensively fixed in formalin. Using this method,
the amplification of the c-erbB-2 oncogene has been detected
in formalin-fixed, paraffin-embedded breast cancer tissues
with a high degree of concordance with the amplification in
fresh tissues (Hyytinen et al., 1994). The negative amplifica-
tion result of the present study by FISH is consistent with the
previous negative findings based on Southern hybridisation
(n= 10) (Burgart et al., 1991) and DNA slot-blotting (n = 10)
of astrocytomas (Schwechheimer et al., 1994). It confirms
that the TA250antibody is highly efficient in the detection of
c-erbB-2 amplification, as has been observed with breast
cancer (Press et al., 1994).
Together, these data show that the mechanism leading to
p185-overexpression, although reported with variable fre-
quency in different studies, is not the amplification of the c-
erbB-2 gene. An increase in gene transcription could be one
possible explanation for the overexpression, but our findings
of the aberrant localisation of the protein in cytoplasm, and
not in cell membranes, suggest that there may be other
reasons for the increased expression. One possibility is
aberrant or incomplete glycosylation of the extracellular
domain of the p185-protein, which could be related to the
defective association of the p185-protein with the cell
membrane (Morali et al., 1993). Another possible explana-
tion is the accumulation of the mutated protein in the cell
due to the increased half-life of the protein, which happens
after p53 mutations in many tumours, including astrocyto-
mas. This is supported by a recent finding of point mutations
in the transmembrane domain of the c-erbB-2 gene of four
out of seven malignant astrocytic neoplasms (Kamitani et at.,
1992).
In conclusion, our results suggest that p185 (c-erbB-2)
overexpression is infrequent in astrocytomas, and that c-
erbB-2 oncogene amplification is not seen in the few cases
in which there is cytoplasmic overexpression. The
diagnostic and prognostic utility of p185 overexpression
is limited. The reason for the phenomenon is unknown,c-erbB-2 in astrocytomas by IHC and FISH X
H Haapasalo et al
623
and the results concerning the frequency of the phenom-
enon are confounding. The immunohistochemistry of p185
does not seem to have clinical value in the evaluation of
astrocytic neoplasms.
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